Phase 2 Peripheral Neuropathy Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who have been diagnosed with typical CIDP, or a specific variant called multifocal CIDP or motor CIDP, based on the 2021 European medical guidelines for diagnosing CIDP.
- People whose nerve conduction or electrical nerve testing results support a CIDP diagnosis, in line with those same European guidelines.
- People who are currently on a stable, ongoing treatment for CIDP — either steroid tablets (taken daily, every other day, or in pulses) or immunoglobulin therapy (given by drip or injection under the skin), with or without low-dose steroids — and have been on that stable treatment for at least 3 months before the screening visit.
Who may not be able to join:
- People who have, or have previously had, a condition called IgM paraproteinemia (an abnormal protein in the blood), with or without related antibodies.
- People whose CIDP is the distal, sensory, or focal type, or who have been diagnosed with a condition called autoimmune nodopathy, based on the European CIDP guidelines.
- People whose nerve condition is caused by something other than CIDP, including conditions such as multifocal motor neuropathy, inherited nerve diseases, POEMS syndrome, lumbosacral nerve disorders, nerve damage related to vitamin deficiencies or cancer, or nerve damage caused by medications or toxic substances.
- People with diabetes who do not have both a confirmed typical CIDP diagnosis and strong nerve test evidence of the specific type of nerve damage associated with CIDP, or where the treating investigator believes the diabetes was poorly controlled before the CIDP diagnosis or at the time of screening.
- People who have a history of spinal cord problems or signs of nerve damage within the brain or spinal cord (central demyelination).
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Phone: 18007970414
Australian sites
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
3 site(s) in Australia. Confirm current status and contact details directly with the trial site.
Primary endpoints
Proportion of participants remaining Relapse-free by Week 24
Can't join this trial?
Data last synced from ClinicalTrials.gov: 15 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.